Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Feb;64(2):677–679. doi: 10.1128/iai.64.2.677-679.1996

Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.

L C Paoletti 1, R C Kennedy 1, T C Chanh 1, D L Kasper 1
PMCID: PMC173821  PMID: 8550227

Abstract

Maternal vaccination has been proposed as a rational approach for the prevention of neonatal group B streptococcal (GBS) disease. In this study, baboons were used as a nonhuman primate model to evaluate the immunogenicity of a GBS type III glycoconjugate vaccine. Type III-specific immunoglobulin G with opsonic activity was induced after vaccination with type III polysaccharide coupled to tetanus toxoid administered with an aluminum adjuvant. This suggests that baboons could be used in evaluating maternal transfer of GBS-specific antibodies by vaccination during pregnancy.

Full Text

The Full Text of this article is available as a PDF (149.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. J., Edwards M. S., Kasper D. L. Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest. 1978 Apr;61(4):1107–1110. doi: 10.1172/JCI109011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker C. J., Edwards M. S., Kasper D. L. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 1981 Oct;68(4):544–549. [PubMed] [Google Scholar]
  3. Baker C. J. Group B streptococcal infections. Adv Intern Med. 1980;25:475–501. [PubMed] [Google Scholar]
  4. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. doi: 10.1056/NEJM197604012941404. [DOI] [PubMed] [Google Scholar]
  5. Baker C. J., Kasper D. L. Group B streptococcal vaccines. Rev Infect Dis. 1985 Jul-Aug;7(4):458–467. doi: 10.1093/clinids/7.4.458. [DOI] [PubMed] [Google Scholar]
  6. Baker C. J., Kasper D. L., Tager IRAB, Paredes A., Alpert S., McCormack W. M., Goroff D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest. 1977 May;59(5):810–818. doi: 10.1172/JCI108703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Baker C. J., Rench M. A., Edwards M. S., Carpenter R. J., Hays B. M., Kasper D. L. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med. 1988 Nov 3;319(18):1180–1185. doi: 10.1056/NEJM198811033191802. [DOI] [PubMed] [Google Scholar]
  8. Baltimore R. S., Kasper D. L., Baker C. J., Goroff D. K. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol. 1977 Feb;118(2):673–678. [PubMed] [Google Scholar]
  9. Gupta R. K., Siber G. R. Adjuvants for human vaccines--current status, problems and future prospects. Vaccine. 1995 Oct;13(14):1263–1276. doi: 10.1016/0264-410x(95)00011-o. [DOI] [PubMed] [Google Scholar]
  10. Lagergard T., Shiloach J., Robbins J. B., Schneerson R. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun. 1990 Mar;58(3):687–694. doi: 10.1128/iai.58.3.687-694.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Madoff L. C., Paoletti L. C., Tai J. Y., Kasper D. L. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest. 1994 Jul;94(1):286–292. doi: 10.1172/JCI117319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Paoletti L. C., Kasper D. L., Michon F., DiFabio J., Jennings H. J., Tosteson T. D., Wessels M. R. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest. 1992 Jan;89(1):203–209. doi: 10.1172/JCI115564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Paoletti L. C., Wessels M. R., Michon F., DiFabio J., Jennings H. J., Kasper D. L. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1992 Oct;60(10):4009–4014. doi: 10.1128/iai.60.10.4009-4014.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Paoletti L. C., Wessels M. R., Rodewald A. K., Shroff A. A., Jennings H. J., Kasper D. L. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1994 Aug;62(8):3236–3243. doi: 10.1128/iai.62.8.3236-3243.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Powell M. F., Cleland J. L., Eastman D. J., Lim A., Murthy K., Newman M. J., Nunberg J. H., Weissburg R. P., Vennari J. C., Wrin T. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons . AIDS Res Hum Retroviruses. 1994;10 (Suppl 2):S105–S108. [PubMed] [Google Scholar]
  16. Schuchat A., Wenger J. D. Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. Epidemiol Rev. 1994;16(2):374–402. doi: 10.1093/oxfordjournals.epirev.a036159. [DOI] [PubMed] [Google Scholar]
  17. Shearer M. H., Jenson H. B., Carey K. D., Chanh T. C., Kennedy R. C. Production and characterization of murine monoclonal antibodies specific for baboon IgG heavy and light chain epitopes. J Med Primatol. 1994 Sep;23(7):382–387. doi: 10.1111/j.1600-0684.1994.tb00124.x. [DOI] [PubMed] [Google Scholar]
  18. Wessels M. R., Paoletti L. C., Kasper D. L., DiFabio J. L., Michon F., Holme K., Jennings H. J. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest. 1990 Nov;86(5):1428–1433. doi: 10.1172/JCI114858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wessels M. R., Paoletti L. C., Pinel J., Kasper D. L. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Infect Dis. 1995 Apr;171(4):879–884. doi: 10.1093/infdis/171.4.879. [DOI] [PubMed] [Google Scholar]
  20. Wessels M. R., Paoletti L. C., Rodewald A. K., Michon F., DiFabio J., Jennings H. J., Kasper D. L. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1993 Nov;61(11):4760–4766. doi: 10.1128/iai.61.11.4760-4766.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wessels M. R., Pozsgay V., Kasper D. L., Jennings H. J. Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem. 1987 Jun 15;262(17):8262–8267. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES